Tags : JHL Biotech

JHL Biotech Reports Dosing of its First Patient with JHL1266

Shots: The study involves assessing of JHL1266 vs Prolia sourced from the EU and the US in healthy human subjects evaluating its PK, PD, and immunogenicity The JHL1266 is proved to be a milestone and an initiative in bringing safe, effective, and high-quality biologics JHL1266 is a mAb targeting RANKL works by inhibition of developed […]Read More

JHL Biotech Reports Randomization of Patients in P-III Study of

Shots:   The study involves assessing of JHL1101 + CHOP (J-CHOP) vs rituximab + CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma  Post P-III Study of JHL1101 and combination therapy, JHL Biotech plans to conduct PK study in RA patients in EU JHL1101 (biosimilar to Rituximab) is a mAb targeting CD20 cells, for […]Read More